TradingKey - Eli Lilly (LLY) rose over 3% in U.S. premarket trading on Thursday, climbing to around $1,488. If these gains carry into regular trading, the stock is poised to set a new all-time high. The primary catalyst driving the bullish market sentiment is that Eli Lilly's oral GLP-1 weight-loss drug, orforglipron calcium tablets, officially received approval from China's National Medical Products Administration (NMPA) under the brand name "Muyouda."

TradingKeyThu, Nov 12

CVS Stock Price Forecast: Shares Plunge 12% to Near Six-Month Low Despite Earnings Beat, Breakup Plan May Push Stock to $70

TradingKey - CVS Health (CVS) reported earnings that beat market expectations for the eighth consecutive quarter, yet failed to win over investors. On November 4, the company announced plans to split its business into two independent publicly traded companies in the first half of 2028. Following the announcement, its stock plunged 12.5% to a near six-month low.

TradingKeyThu, Nov 5

Regeneron Stock Forecast: REGN Jumps 13% as Full Dupixent Profits Kick In, With $930.46 the Next Test

TradingKey - Regeneron stock forecast: REGN jumped 13.33% after a big Q3 beat driven by full Dupixent profits, with $930.46 the next test and RSI overbought.

TradingKeyMon, Nov 2

AstraZeneca Q3 Revenue Rises 7%, $1.5 Billion Cost-Cutting Plan Lifts Shares Over 5% Pre-Market

TradingKey - On October 30, AstraZeneca (AZN) shares rose more than 5% in pre-market trading. The company's third-quarter revenue and earnings both exceeded market expectations, while it reaffirmed its full-year guidance and announced a restructuring plan expected to unlock $1.5 billion in annual benefits, bolstering investor confidence in its medium- to long-term growth prospects.

TradingKeyFri, Oct 30

Eli Lilly Q3 Revenue Surges 39% and Raises Full-Year Guidance as Weight-Loss Drug Demand Drives Stock Up Over 5% Pre-Market

TradingKey - On October 29, Eli Lilly (LLY) reported third-quarter results that beat market expectations and raised its full-year revenue guidance once again. Driven by sustained growth in demand for Mounjaro and Zepbound, the company's quarterly revenue reached $24.397 billion, up 39% year-over-year and significantly above Wall Street's forecast of approximately $22.6 billion. Following the announcement, Eli Lilly's stock rose more than 5% in pre-market trading.

TradingKeyThu, Oct 29

Moderna Stock Forecast: MRNA Holds $181.36 Support After Positive Cancer Vaccine Data Sparks a Selloff

TradingKey - Moderna stock forecast: MRNA falls 19% in two days despite positive melanoma vaccine data, with $181.36 support now deciding whether the uptrend holds.

TradingKeyMon, Oct 26